ImmunityBio, Inc. (IBRX)
10.51
+0.60
(+6.05%)
USD |
NASDAQ |
Oct 09, 16:00
10.59
+0.08
(+0.76%)
After-Hours: 20:00
ImmunityBio Cash from Operations (Quarterly) : -66.49M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -66.49M |
| March 31, 2026 | -75.36M |
| December 31, 2025 | -70.38M |
| September 30, 2025 | -68.91M |
| June 30, 2025 | -79.75M |
| March 31, 2025 | -85.90M |
| December 31, 2024 | -85.14M |
| September 30, 2024 | -98.76M |
| June 30, 2024 | -100.34M |
| March 31, 2024 | -106.98M |
| December 31, 2023 | -115.27M |
| September 30, 2023 | -87.40M |
| June 30, 2023 | -79.77M |
| March 31, 2023 | -84.31M |
| December 31, 2022 | -90.73M |
| September 30, 2022 | -80.60M |
| June 30, 2022 | -91.25M |
| March 31, 2022 | -74.93M |
| December 31, 2021 | -71.64M |
| September 30, 2021 | -72.72M |
| June 30, 2021 | -69.60M |
| March 31, 2021 | -60.47M |
| December 31, 2020 | -23.06M |
| September 30, 2020 | -18.28M |
| June 30, 2020 | -16.52M |
| Date | Value |
|---|---|
| March 31, 2020 | -12.60M |
| December 31, 2019 | -14.88M |
| September 30, 2019 | -16.57M |
| June 30, 2019 | -16.83M |
| March 31, 2019 | -13.08M |
| December 31, 2018 | -14.03M |
| September 30, 2018 | -17.57M |
| June 30, 2018 | -16.27M |
| March 31, 2018 | -15.51M |
| December 31, 2017 | -13.64M |
| September 30, 2017 | -10.13M |
| June 30, 2017 | -14.95M |
| March 31, 2017 | -10.06M |
| December 31, 2016 | -10.75M |
| September 30, 2016 | -10.68M |
| June 30, 2016 | -8.301M |
| March 31, 2016 | -8.856M |
| December 31, 2015 | -11.08M |
| September 30, 2015 | -4.178M |
| June 30, 2015 | -8.14M |
| March 31, 2015 | -1.902M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | -0.256M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -107.47M |
| Cash from Financing (Quarterly) | 44.44M |
| Free Cash Flow | -288.51M |
| Free Cash Flow Per Share (Quarterly) | -0.0667 |
| Free Cash Flow to Equity (Quarterly) | -173.83M |
| Free Cash Flow to Firm (Quarterly) | -38.79M |
| Free Cash Flow Yield | -2.74% |